Hypoxia and Hypoxia-Inducible Factor-1 Expression Enhance Osteolytic Bone Metastases of Breast Cancer
- 1 May 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (9) , 4157-4163
Abstract
Hypoxia is a common feature of solid tumors and is associated with their malignant phenotype. The transcription factor hypoxia-inducible factor-1 (HIF-1) is a major regulator of adaptation to hypoxia and is implicated in the malignant progression of cancers. Here, we studied whether hypoxia and HIF-1 expression contribute to the development of bone metastases using a well-characterized animal model of bone metastasis in MDA-MB-231 human breast cancer cells. To study the role of hypoxia in bone metastases, we tested the effects of the fusion protein (TOP3), the oxygen-dependent degradation domain of HIF-1α fused with HIV-TAT, and procaspase-3. TOP3 selectively induced apoptosis in hypoxic tumor cells in vitro and significantly reduced bone metastases in vivo. We next examined the role of HIF-1 in bone metastases by establishing MDA-MB-231 cells overexpressing constitutively active or dominant-negative HIF-1α (MDA/CA-HIF or MDA/DN-HIF, respectively). Bone metastases of MDA/CA-HIF were significantly increased with elevated number of CD31-positive blood vessels. In contrast, bone metastases were significantly reduced in MDA/DN-HIF. Because the progression of osteolytic bone metastases is due in part to the imbalance between bone formation and bone resorption, we examined the effects of hypoxia and HIF-1 on the differentiation of osteoblasts and osteoclasts. Hypoxia and CA-HIF overexpression markedly inhibited osteoblastic differentiation, whereas hypoxia increased osteoclast-like cell formation. In conclusion, these results suggest that tumor-associated hypoxia and HIF-1 expression promote the progression of bone metastases in breast cancer. Our results also suggest that hypoxia and HIF-1 lead to the development of osteolytic bone metastases by suppressing osteoblast differentiation and promoting osteoclastogenesis. [Cancer Res 2007;67(9):4157–63]Keywords
All Related Versions
This publication has 36 references indexed in Scilit:
- Hypoxic stress enhances osteoclast differentiation via increasing IGF2 production by non-osteoclastic cellsBiochemical and Biophysical Research Communications, 2005
- Transient Changes in Oxygen Tension Inhibit Osteogenic Differentiation and Runx2 Expression in OsteoblastsJournal of Biological Chemistry, 2004
- Nitric Oxide Induces Hypoxia-inducible Factor 1 Activation That Is Dependent on MAPK and Phosphatidylinositol 3-Kinase SignalingJournal of Biological Chemistry, 2004
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- Ultrastructural and cytobiological studies on possible interactions between PTHrP-secreting tumor cells, stromal cells, and bone cellsJournal of Bone and Mineral Metabolism, 2003
- Metabolic Acidosis Stimulates RANKL RNA Expression in Bone Through a Cyclo-oxygenase-Dependent MechanismJournal of Bone and Mineral Research, 2003
- Hypoxia is a major stimulator of osteoclast formation and bone resorptionJournal of Cellular Physiology, 2003
- Increased expression of bone morphogenetic protein‐7 in bone metastatic prostate cancerThe Prostate, 2003
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the MouseScience, 1999